William Blair Predicts Sight Sciences Q1 Earnings

Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Sight Sciences in a report issued on Friday, May 9th. William Blair analyst M. Andrew anticipates that the company will post earnings of ($0.27) per share for the quarter. The consensus estimate for Sight Sciences' current full-year earnings is ($0.99) per share. William Blair also issued estimates for Sight Sciences' Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.28) EPS and Q4 2026 earnings at ($0.24) EPS.

A number of other analysts also recently commented on SGHT. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. Citigroup reduced their target price on Sight Sciences from $4.60 to $3.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Stifel Nicolaus dropped their target price on shares of Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. UBS Group reduced their price target on shares of Sight Sciences from $5.50 to $5.00 and set a "buy" rating for the company in a research report on Monday, January 27th. Finally, Lake Street Capital lifted their price objective on shares of Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a research report on Friday, May 9th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $3.92.

Sight Sciences Price Performance

Sight Sciences stock traded up $0.10 during midday trading on Monday, hitting $3.52. The company's stock had a trading volume of 36,780 shares, compared to its average volume of 236,385. Sight Sciences has a 12 month low of $2.03 and a 12 month high of $8.45. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $181.71 million, a PE ratio of -3.45 and a beta of 2.41. The stock's 50-day moving average price is $2.76 and its 200-day moving average price is $3.19.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The firm had revenue of $17.51 million for the quarter, compared to analysts' expectations of $16.51 million.

Institutional Investors Weigh In On Sight Sciences

Several institutional investors have recently made changes to their positions in the company. KCK LTD. acquired a new position in Sight Sciences in the fourth quarter worth approximately $15,925,000. Long Focus Capital Management LLC increased its stake in shares of Sight Sciences by 39.7% during the 1st quarter. Long Focus Capital Management LLC now owns 3,126,508 shares of the company's stock worth $7,504,000 after purchasing an additional 887,876 shares during the last quarter. Prosight Management LP raised its holdings in shares of Sight Sciences by 71.1% during the 4th quarter. Prosight Management LP now owns 908,847 shares of the company's stock valued at $3,308,000 after purchasing an additional 377,625 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Sight Sciences by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 792,860 shares of the company's stock valued at $2,887,000 after purchasing an additional 8,731 shares during the last quarter. Finally, B Group Inc. acquired a new stake in shares of Sight Sciences in the 4th quarter valued at $2,291,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Sight Sciences

In other news, EVP Manohar K. Raheja acquired 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was acquired at an average cost of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the acquisition, the executive vice president now owns 145,000 shares in the company, valued at approximately $395,850. The trade was a 7.41% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paul Badawi sold 24,174 shares of the business's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the completion of the transaction, the chief executive officer now owns 6,010,580 shares in the company, valued at $13,824,334. This trade represents a 0.40% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,196 shares of company stock valued at $81,001. Corporate insiders own 30.90% of the company's stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.